A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF
Latest Information Update: 30 May 2025
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms MIST
- Sponsors Avalyn Pharma
Most Recent Events
- 27 May 2025 According to Avalyn Pharma Media release, company announced presentation of study design at the European Congress of Rheumatology (EULAR) 2025, being held June 11-14, 2025, in Barcelona, Spain.
- 06 May 2025 According to Avalyn Pharma Media release, Joyce Lee is an investigator of this study.
- 11 Sep 2024 Study design presented at the 34th Annual Congress of the European Respiratory Society.